Navigation Links
IVI granted 2 US patents on dysentery vaccine inventions

SEOUL, KOREA The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide. This infectious disease, caused by the bacterial pathogen Shigella, is a major health problem in developing countries, as young children are particularly vulnerable to the disease. The United States Patent and Trademark Office recently issued two patents on "Novel Shigella protein antigens and methods" to IVI. These two patents will accelerate the Institute's current efforts in developing an effective and low-cost vaccine for use among impoverished communities afflicted by dysentery.

The Shigella vaccine patents, which will expire in 2029, are the most recently issued patents of IVI. IVI filed these two patents (Applications No. 12/603,574 and No. 12/692,187) following its discovery of novel common protein antigens in several Shigella species that could be used as the basis of a universal vaccine against bacillary dysentery. With the potential to provide cross-protection across species and serotypes of Shigella, this could be the first broadly protective vaccine against dysentery. The patents claim vaccine compositions comprising either of two novel conserved Shigella proteins and a conjugate molecule comprising an O-specific polysaccharide antigen of Shigella bacteria covalently bound to either of these Shigella proteins.

Dr. Cecil Czerkinsky, IVI's Deputy Director-General of Laboratory Sciences and Dr. Dong Wook Kim, Associate Professor at Hanyang University and former IVI scientist, reported the original discovery of the Shigella common protein antigens in a provisional patent application filed in October 2008. Dr. Czerkinsky commented, "We are extremely excited about the issuance of the Shigella vaccine patents. It further reinforces our belief that these common proteins, through their immunological properties, may be highly effective in preventing shigellosis, a diarrheal disease that claims countless lives of children every year, mainly in developing countries."

"This patent issuance is an important milestone on IVI's path of delivering a new vaccine against another killer infectious disease," added Dr. Christian Loucq, IVI's Director-General. "Furthermore, it underlies the dynamism and productivity of IVI scientists."


Contact: Tae Kyung Byun
International Vaccine Institute

Related biology news :

1. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
2. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
3. Company Granted Patent on Apparatus, Systems, and Methods for Gathering and Processing Wireless Biometric and Biomechanical Data
4. BIO-key(R) Granted Patent for Trusted Biometric Device Security Solution
5. 2009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
6. BIO-key(R) Granted Patent to Secure Biometric Enrollments From Unauthorized Use
7. BIO-key(R) Granted Additional Patent for Biometric Security Solution
8. U.S. Supreme Court petitioned to review AMP, et al. lawsuit on gene patents
9. US Patent Office affirms Zamore Design Rule patents
10. Digital data forensic expert at NJIT to be feted by R&D council for data hiding patents
11. IEEE-USA pleased that Supreme Courts ruling preserves software patents
Post Your Comments:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology: